ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical Need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Nordwest Hospital Frankfurt, Darmstadt Clinic and leading experts as well as an outstanding network of scientific and clinical advisors. Today, ORYX is developing three clinical cancer immunotherapy projects (an oncolytic virus and two therapeutic cancer vaccines) in indications with high unmet medical need. All three projects successfully completed Phase I/IIa clinical trials and are available for outlicensing to Pharma or Biotech companies. www.oryx-medicine.com Imprint: ORYX GmbH & Co. KG Marktplatz 1 85598 Baldham, Germany Phone: +49-8106-21 311-0 info@oryx-medicine.com Entered in the Commercial Register at Munich District Court: HR A 90888 VAT identification number: DE258 096 724 General Partner ORYX Verwaltungs GmbH, München Managing Director: Dr. Bernard Huber